{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:20:11Z","timestamp":1784866811431,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.cca.2013.12.011","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:30:36Z","timestamp":1387326636000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients"],"prefix":"10.1016","volume":"429","author":[{"given":"Masaki","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2013.12.011_bb0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0885-3924(03)00068-X","article-title":"Cancer pain management and the JCAHO's pain standards: an institutional challenge","volume":"25","author":"Cohen","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.cca.2013.12.011_bb0010","first-page":"1","article-title":"Opioid guidelines in the management of chronic non-cancer pain","volume":"9","author":"Trescot","year":"2006","journal-title":"Pain Physician"},{"key":"10.1016\/j.cca.2013.12.011_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","article-title":"Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review","volume":"4","author":"McNicol","year":"2003","journal-title":"J Pain"},{"key":"10.1016\/j.cca.2013.12.011_bb0020","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: an evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2013.12.011_bb0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0009-9236(03)00152-8","article-title":"Side effects of opioids during short-term administration: effect of age, gender, and race","volume":"74","author":"Cepeda","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2013.12.011_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1185\/03007999209115221","article-title":"The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene\/paracetamol tablets in patients with severe osteoarthritis of the hips","volume":"13","author":"Lloyd","year":"1992","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cca.2013.12.011_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199302000-00001","article-title":"Pharmacological mechanisms of opioid analgesics","volume":"16","author":"Pasternak","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cca.2013.12.011_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1476-5381.1981.tb10998.x","article-title":"Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog","volume":"72","author":"Bhargava","year":"1981","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cca.2013.12.011_bb0045","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00520-009-0775-3","article-title":"Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients","volume":"18","author":"Ishihara","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cca.2013.12.011_bb0050","first-page":"307","article-title":"Extrapyramidal reactions to metoclopramide and prochlorperazine","volume":"71","author":"Bateman","year":"1989","journal-title":"Q J Med"},{"key":"10.1016\/j.cca.2013.12.011_bb0055","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2125.1991.tb03973.x","article-title":"Clinical pharmacology of prochlorperazine in healthy young males","volume":"32","author":"Isah","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2013.12.011_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jemermed.2003.11.011","article-title":"Diphenhydramine in the treatment of akathisia induced by prochlorperazine","volume":"26","author":"Vinson","year":"2004","journal-title":"J Emerg Med"},{"key":"10.1016\/j.cca.2013.12.011_bb0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/bmc.1725","article-title":"Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry","volume":"26","author":"Tashiro","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.cca.2013.12.011_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00589893","article-title":"Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels","volume":"99","author":"Baron","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.cca.2013.12.011_bb0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/edrv-6-4-564","article-title":"Dopamine: a prolactin-inhibiting hormone","volume":"6","author":"Ben-Jonathan","year":"1985","journal-title":"Endocr Rev"},{"key":"10.1016\/j.cca.2013.12.011_bb0080","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.cca.2013.12.011_bb0085","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-5347(25)00377-5","article-title":"Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion","volume":"240","author":"Bero","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cca.2013.12.011_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000126176","article-title":"Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin","volume":"55","author":"Flores","year":"1992","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.cca.2013.12.011_bb0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2265.1983.tb00017.x","article-title":"The participation of hypothalamic dopamine in morphine-induced prolactin release in man","volume":"19","author":"Delitala","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cca.2013.12.011_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0015-0282(16)46101-7","article-title":"Effect of morphine on the hypothalamic-pituitary axis in postmenopausal women","volume":"37","author":"Hemmings","year":"1982","journal-title":"Fertil Steril"},{"key":"10.1016\/j.cca.2013.12.011_bb0105","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2013.12.011_bb0110","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2013.12.011_bb0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00540-008-0661-z","article-title":"Dopamine D2 receptor Taq IA polymorphism is associated with postoperative nausea and vomiting","volume":"22","author":"Nakagawa","year":"2008","journal-title":"J Anesth"},{"key":"10.1016\/j.cca.2013.12.011_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YPG.0b013e3283437250","article-title":"Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia","volume":"21","author":"Zahari","year":"2011","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.cca.2013.12.011_bb0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cca.2013.12.011_bb0130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.cca.2013.12.011_bb0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000542-200608000-00016","article-title":"Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy","volume":"105","author":"Chou","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cca.2013.12.011_bb0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1472-8206.2009.00781.x","article-title":"The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes","volume":"24","author":"Zwisler","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cca.2013.12.011_bb0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CPP43163","article-title":"Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients","volume":"43","author":"Nakazono","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2013.12.011_bb0150","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/2.12.2197-a","article-title":"PCR detection of the TaqA RFLP at the DRD2 locus","volume":"2","author":"Grandy","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cca.2013.12.011_bb0155","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000542-200503000-00008","article-title":"Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response","volume":"102","author":"Romberg","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cca.2013.12.011_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2125.1987.tb03021.x","article-title":"Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers","volume":"23","author":"Taylor","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2013.12.011_bb0165","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.cca.2013.12.011_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0888-7543(91)90431-D","article-title":"Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene","volume":"10","author":"Hauge","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/j.cca.2013.12.011_bb0175","first-page":"1109","article-title":"Side effects of opioid and gene variants","volume":"58","author":"Sora","year":"2009","journal-title":"Masui"},{"key":"10.1016\/j.cca.2013.12.011_bb0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.cca.2013.12.011_bb0185","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","article-title":"Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients","volume":"32","author":"Yasui-Furukori","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.cca.2013.12.011_bb0190","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1210\/endo-125-4-1863","article-title":"Fentanyl stimulates prolactin release through mu-opiate receptors, but not the serotonergic system","volume":"125","author":"Pan","year":"1989","journal-title":"Endocrinology"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898113005068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:35:54Z","timestamp":1746081354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898113005068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":38,"alternative-id":["S0009898113005068"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2013.12.011","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2013.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}